 |
More: American Society of Clinical Oncology (ASCO) 44th Annual Meeting Oncology Insights: 2008 Annual ASCO Meeting Highlights Edition CME May 30, 2008 - June 3, 2008, Chicago, Illinois Author Information and Disclosures This activity is not sanctioned by, nor a part of, the American Society of Clinical Oncology.
Release Date: June 24, 2008; Valid for credit through June 24, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Oncology Insights: 2008 Annual ASCO Meeting Highlights EditionLouis M. Weiner, MD; Maurie Markman, MD; Richard M. Stone, MD; Roy S. Herbst, MD, PhD; Fredrick B. Hagemeister, MDAvailable As: Slides/Video | Slides/Transcript
Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Clinical Oncology. These materials and the related activity are not sanctioned by the American Society of Clinical Oncology or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe important trials and findings reported at the 2008 annual ASCO meeting with respect to gynecologic cancers (ovarian, cervix), non-small cell lung cancers, myelofibrosis, Hodgkin disease, and lymphomas
- Discuss clinical implications of
new data
- Explain remaining questions to be addressed in future clinical trials
Authors and Disclosures Louis M. Weiner, MD
Disclosure: Louis M. Weiner, MD, has disclosed that he has received grants for clinical research from and served as an advisor or consultant to Amgen.
Maurie Markman, MD
Disclosure: Maurie Markman, MD, has disclosed that he has served as an advisor or consultant to Eli Lilly, OBI, Tibotec, Celligent, and Genentech. Richard M. Stone, MD
Disclosure: Richard M. Stone, MD, has disclosed that he has received grants for clinical research from Novartis and Bristol-Myers Squibb. Dr Stone has also disclosed that he has served as an
advisor or consultant to Merck, Genzyme, Hana Biosciences, Johnson & Johnson, and CSL. Dr. Stone has also disclosed that he has received grants for educational activities from Bristol-Myers Squibb, Pharmion, and Cellgene. Roy S. Herbst, MD, PhD
Disclosure: Roy S. Herbst, MD, PhD, has disclosed that he has received grants for clinical research and educational activities from and served as an advisor or consultant to
Eli Lilly, Genentech, Amgen, and Bristol-Myers Squibb. Fredrick B. Hagemeister, MD
Disclosure: Fredrick B. Hagemeister, MD, has disclosed that he has served as a speaker for Biogen Idec, Genentech, Cephalon, Roche, and Millennium. Dr. Hagemeister has also disclosed that he has received grants for clinical research from Novartis. Margie Miller
Disclosure:
Margie Miller has disclosed no relevant financial relationships. Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
